TITLE

Recently Approved

PUB. DATE
November 2006
SOURCE
Pharmaceutical Representative;Nov2006, Vol. 36 Issue 11, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents several drugs that are recently approved by the Food and Drug Administration in the U.S. It includes Fentora (fentanyl buccal tablet) from Cephalon Inc. to reduce pain in the opioid therapy of cancer patients, GlaxosmithKline PLC's Lamictal (lamotrigine) tablets as adjunctive therapy for Lennox-Gastraut syndrome's seizures and maintenance treatment of bipolar 1 disorder, and Keppra (levetiracetam) from UCB Pharma Inc. for treatment of juvenile myoclonic epilepsy's seizures.
ACCESSION #
23101230

 

Related Articles

  • Decision Update.  // PharmaWatch: Biotechnology;Jun2008, Vol. 7 Issue 6, p11 

    The article presents updates on the status of drugs currently developed by biopharmaceutical companies. The U.S. Food and Drug Administration (FDA) recommends Lev Pharmaceuticals Inc.'s Cinryze for treatment of hereditary angioedema. The European Commission has approved Cephalon Inc.'s Effentora...

  • Keppra approved in oral formulation.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p14 

    Reports on the approval of the U.S. Food and Drug Administration to UCB Pharma Inc.'s Keppra oral solution. Use of Keppra in treating patients with epilepsy; Administration of Keppra oral solution; Safety and efficacy of the drug for the treatment of epilepsy.

  • FDA initiates safety review of TNF blockers.  // PharmaWatch: Biotechnology;Jul2008, Vol. 7 Issue 7, p9 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to investigate a possible association between anti-tumor necrosis factor (TNF) blockers and childhood cancer. It reports that FDA will review the cancer risk over six months, however UCB Pharma will need to provide...

  • Ofatumumab approved for advanced CLL. Traynor, Kate // American Journal of Health-System Pharmacy;12/1/2009, Vol. 66 Issue 23, p2062 

    The article reports on the approval by the Food and Drug Administration on ofatumumab for the treatment of chronic lymphocytic leukemia (CLL) in the U.S. It is stated that the said drug from GlaxoSmithKline and Benmab A/S is used for the treatment of CLL patients whose cancer does not respond to...

  • Ofatumumab approved for advanced CLL. Traynor, Kate // American Journal of Health-System Pharmacy;12/1/2009, Vol. 66 Issue 23, p2062 

    The article reports on the approval by the Food and Drug Administration on ofatumumab for the treatment of chronic lymphocytic leukemia (CLL) in the U.S. It is stated that the said drug from GlaxoSmithKline and Benmab A/S is used for the treatment of CLL patients whose cancer does not respond to...

  • American Academy of Neurology.  // BioWorld Today;4/15/2010, Vol. 21 Issue 72, p4 

    The article reports that UCB Pharma Inc. is negotiating with the U.S. Food and Drug Administration (FDA) to make Neupro, a rotigotine transdermal system, to be available to patients with early state Parkinson's disease as soon as possible.

  • Consumer Media Versus FDA. Henderson, Lisa // Applied Clinical Trials;Aug2007, Vol. 16 Issue 8, p12 

    The author reflects on the issues concerning the postmarketing drug newsletter of the pharmaceutical industries in the U.S. She states that the Food and Drug Administration (FDA) has intended to launch a newsletter on its web site to inform the public about drug safety, but she stresses that...

  • Parkinson's Update.  // PharmaWatch: CNS;Jun2010, Vol. 9 Issue 6, p10 

    The article offers world news briefs related to pharmaceutical industry. Aton Pharma Inc. acquires the U.S. marketing rights to Lodosyn tablets from Bristol-Myers Squibb Co. UCB Pharma Inc. receives a complete response letter from the U.S. Food and Drug Administration (FDA) recommending...

  • FDA actions in brief.  // Formulary;May2006, Vol. 41 Issue 5, p213 

    The article presents news briefs on drugs approved by the U.S. Food and Drug Administration. Included are the Naltrexone extended-release injectable suspension (Vivitrol) of Alkermes Inc. and Cephalon Inc., for the treatment of alcohol independence, and the Zanamivir inhalation powder (Relenza),...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics